Skip to main content
TipRanks
Go Ultimate75% OFF

RxSight (RXST) Q3 2026 Earnings Report

250 Followers

RXST Q3 2026 EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.08
One Year Ago EPS
-$0.24

RXST Q3 2026 Revenue Results

Actual Revenue
$24.59M
Expected Revenue
$27.19M
Beat/Miss
Missed by -$2.61M
YoY Revenue Growth
-18.97%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
After Close
Conference Call
Tuesday, November 3, 2026
RXST Upcoming Earnings

RxSight's next earnings date is estimated for March 3, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

RXST Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:9.15%|
Earnings Call Sentiment|Positive

The call had a mixed but cautiously positive tone. Third-quarter financial results were weak, with revenue down 19%, LAL procedure volume down 11%, lower gross margin, and continued competitive and operational disruption. However, management expressed confidence in LAL's physician-validated differentiation, the nearly doubled sales force, the next-generation pipeline, the Alcon collaboration, and restructuring actions expected to reduce 2027 operating expenses while supporting strategic investment.

Company Guidance

The company is not providing formal guidance for full year 2026 and intends to resume providing financial guidance for 2027 when it reports fourth quarter results early next year; for Q4, management anticipates Q4 LAL sales at least to look more in line with what we saw in Q2, which implies revenue growth in the mid- to high single-digit range, while continued competitive activity, ongoing product trialing, and potential disruption from restructuring are expected to influence performance for the remainder of this year. The restructuring is expected to generate meaningful expense savings in the base business, with the impact realized in 2027 and beyond, and the company expects lower OpEx spend in 2027 versus what you'll see in 2026. Management expects fairly limited LDD sales going forward, a handful, and said 2028 is the earliest we could see next-generation LAL approval.

  • Clear Strategic Priorities EstablishedManagement completed its initial assessment and identified three priorities: strengthen the U.S. LAL business, advance the next-generation adjustable lens pipeline, and execute on the Alcon collaboration.
  • U.S. Sales Force Nearly DoubledRxSight has nearly doubled its U.S. sales force, adding representatives with extensive eye-care experience and established physician relationships. The expanded team is intended to increase customer engagement, improve practice integration, and drive deeper LAL utilization.
  • Commercial Leadership StrengthenedThe company appointed Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy. Management said both have strong track records in ophthalmic commercial strategy and that key customers expressed enthusiasm about the appointments.
  • Physician Support and LAL Differentiation Remain StrongManagement reported continued physician enthusiasm for LAL and its differentiated visual outcomes. At the American Academy of Ophthalmology meeting, physicians discussed adjustability, outcomes in patients with prior corneal refractive surgery, and blended-vision strategies. One physician reported choosing LAL for his own brother, who was described as spectacle-free and very satisfied with the results.
  • Strength in High-Utilization PracticesManagement said some top surgeons and practices are growing despite broader pressure. A Seattle clinic recently celebrated its 5,000th RxSight lens placement. Strong-performing practices were associated with more frequent sales-team engagement, better workflow integration, staff training, and familiarity with the supporting data.
  • Next-Generation LAL Pipeline AdvancingRxSight is developing a next-generation adjustable lens intended to expand the eligible patient population, reduce the number of visits required for lock-in, and improve the surgical user experience. Management said 2028 is the earliest possible approval timing, with considerable work still required, and that further milestones are expected to be discussed with 2027 guidance.
  • Alcon Collaboration Passed Key 120-Day MilestoneThe company reported strong early progress with Alcon and said the initial 120-day period had been completed. The milestone solidified the $60 million upfront payment and the ability to move forward with the agreement. Management said the teams have met several times, discussions are robust, and progress is positive.
  • Restructuring Expected to Generate SavingsRxSight completed a significant restructuring across manufacturing, corporate functions, and international operations. Management expects meaningful expense savings in the base business, with the impact realized in 2027 and beyond, while continuing to fund the Alcon collaboration, U.S. commercial expansion, and next-generation LAL development.
  • Lower 2027 OpEx Expected Despite Targeted InvestmentsManagement expects total operating expenses in 2027 to be lower than in 2026, even while investing incrementally in the larger sales organization, the Alcon collaboration, and the next-generation LAL platform.
  • Strong Liquidity PositionRxSight ended the third quarter with $254.7 million in cash, cash equivalents, and short-term investments, including the $60 million Alcon collaboration upfront payment.
  • LDD Pricing Stable and Flexible Rental Option SupportedThe company reported three LDD sales and one rental in the third quarter. Management said LDD average selling prices were stable with no material change from historical levels and that customers have provided positive feedback on the rental option.
  • Q4 LAL Revenue Expected to Improve SequentiallyManagement expects fourth-quarter LAL sales to be more in line with the second quarter. This implies mid- to high-single-digit sequential revenue growth, supported by less seasonality than in the third quarter and encouraging October trends.
  • Commercial Challenges Identified as AddressableManagement said the primary barriers to greater LAL utilization are insufficient customer engagement, workflow and staff-training needs, and clearer guidance on appropriate patient selection. It stated that these challenges can be addressed through the revised commercial strategy and that it sees no structural market issue preventing improvement.
  • Data-Driven Sales Execution Being ImplementedThe company is introducing greater measurement of customer-contact frequency, customer segmentation, surgeon utilization depth, and cohort performance. Management expects to provide more detail on these key performance indicators with 2027 guidance.
  • Patient Flow Has StabilizedManagement characterized the overall surgical market as slightly soft but not dramatically soft. Patient flow had rebounded somewhat from the beginning of the year and was described as relatively stable in the second and third quarters, although not robust.

RXST Earnings History

RXST earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 03, 20272026 (Q4)0.25--0.22――
Nov 03, 20262026 (Q3)-0.31-0.39-0.24-62.50% (-0.15)
Aug 05, 20262026 (Q2)-0.33-0.29-0.290.00% (+0.00)
May 06, 20262026 (Q1)-0.30-0.38-0.2-90.00% (-0.18)
Feb 25, 20262025 (Q4)-0.34-0.22-0.15-46.67% (-0.07)
Nov 05, 20252025 (Q3)-0.38-0.24-0.16-50.00% (-0.08)
Aug 07, 20252025 (Q2)-0.25-0.29-0.16-81.25% (-0.13)
May 07, 20252025 (Q1)-0.22-0.20-0.2520.00% (+0.05)
Feb 25, 20252024 (Q4)-0.17-0.15-0.2642.31% (+0.11)
Nov 07, 20242024 (Q3)-0.25-0.16-0.3554.29% (+0.19)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed